Favipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower Than Targeted

Hdl Handle:
http://hdl.handle.net/10144/618815
Title:
Favipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower Than Targeted
Authors:
Nguyen, TH; Guedj, J; Anglaret, X; Laouénan, C; Madelain, V; Taburet, AM; Baize, S; Sissoko, D; Pastorino, B; Rodallec, A; Piorkowski, G; Carazo, S; Conde, MN; Gala, JL; Bore, JA; Carbonnelle, C; Jacquot, F; Raoul, H; Malvy, D; de Lamballerie, X; Mentré, F
Journal:
PLoS Neglected Tropical Diseases
Abstract:
In 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen. Here we report the favipiravir plasma concentrations that were achieved in participants in the JIKI trial and put them in perspective with the model-based targeted concentrations.
Publisher:
PLoS
Issue Date:
23-Feb-2017
URI:
http://hdl.handle.net/10144/618815
DOI:
10.1371/journal.pntd.0005389
PubMed ID:
28231247
Submitted date:
2017-02-27
Language:
en
ISSN:
1935-2735
Appears in Collections:
Other Diseases

Full metadata record

DC FieldValue Language
dc.contributor.authorNguyen, THen
dc.contributor.authorGuedj, Jen
dc.contributor.authorAnglaret, Xen
dc.contributor.authorLaouénan, Cen
dc.contributor.authorMadelain, Ven
dc.contributor.authorTaburet, AMen
dc.contributor.authorBaize, Sen
dc.contributor.authorSissoko, Den
dc.contributor.authorPastorino, Ben
dc.contributor.authorRodallec, Aen
dc.contributor.authorPiorkowski, Gen
dc.contributor.authorCarazo, Sen
dc.contributor.authorConde, MNen
dc.contributor.authorGala, JLen
dc.contributor.authorBore, JAen
dc.contributor.authorCarbonnelle, Cen
dc.contributor.authorJacquot, Fen
dc.contributor.authorRaoul, Hen
dc.contributor.authorMalvy, Den
dc.contributor.authorde Lamballerie, Xen
dc.contributor.authorMentré, Fen
dc.date.accessioned2017-02-28T21:36:41Z-
dc.date.available2017-02-28T21:36:41Z-
dc.date.issued2017-02-23-
dc.date.submitted2017-02-27-
dc.identifier.citationFavipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower Than Targeted. 2017, 11 (2):e0005389 PLoS Negl Trop Disen
dc.identifier.issn1935-2735-
dc.identifier.pmid28231247-
dc.identifier.doi10.1371/journal.pntd.0005389-
dc.identifier.urihttp://hdl.handle.net/10144/618815-
dc.description.abstractIn 2014-2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus (EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used before for this indication and that high concentrations of the drugs were needed to achieve antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose relevant dosing regimen. Here we report the favipiravir plasma concentrations that were achieved in participants in the JIKI trial and put them in perspective with the model-based targeted concentrations.en
dc.language.isoenen
dc.publisherPLoSen
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseases.en
dc.titleFavipiravir Pharmacokinetics in Ebola-Infected Patients of the JIKI Trial Reveals Concentrations Lower Than Targeteden
dc.identifier.journalPLoS Neglected Tropical Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.